Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Noxopharm.
RELATED STOCKHEAD STORIES
Health & Biotech
ASX Health Stocks: IDT shoots 20pc on COVID-19 deal with government, ImpediMed granted US FDA Breakthrough
News
Market Highlights and 5 ASX Small Caps to watch on Monday
Health & Biotech
ASX health stocks: dorsaVi leads the pack with 12% jump on major contract extension
Stockhead TV
V-Con: Talking medical innovations and breakthrough treatments with ASX biotechs
Health & Biotech
Check Up: As Alzheimer’s grabs the spotlight, these ASX biotech stocks also impressed
News
Closing Bell: Today’s biggest small cap movers on the ASX
News
Market highlights and 5 ASX small caps to watch on Monday
News
Closing Bell: Today’s biggest small cap movers on the ASX
News
Last Orders: ASX 200 rebounds, but the IT sector slumps 10 per cent for the week
News
Market highlights and 5 ASX small caps to watch on Friday
Health & Biotech
Cancer trial to test Noxopharm’s Veyonda with Opdivo
Health & Biotech
Noxopharm study ‘heralds new era’ in treatment of late stage prostate cancer
Health & Biotech
Clinical Trials Tracker: 2022 and beyond
News
Rise and Shine: What you need to know before the ASX opens
News
Rise and Shine: What you need to know before the ASX opens
Health & Biotech
The ASX biotech companies that lost puff on Pfizer vaccine news
Health & Biotech
